For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Dendritic Cell-Derived Tumor Necrosis Factor α Modifies Airway Epithelial Cell ResponsesLutfi R.a · Ledford J.R.a · Zhou P.a · Lewkowich I.P.b · Page K.a–c
Divisions of aCritical Care Medicine and bImmunobiology, Cincinnati Children’s Hospital Medical Center and Cincinnati Children’s Research Foundation, and cDepartment of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA Corresponding Author
Dr. Kristen Page
Division of Critical Care Medicine, Cincinnati Children’s Hospital Medical Center
3333 Burnet Avenue, ML 7006
Cincinnati, OH 45229 (USA)
Tel. +1 513 636 3079, E-Mail firstname.lastname@example.org
Mucosal dendritic cells (DC) are intimately associated with the airway epithelium and thus are ideally situated to be first responders to pathogens. We hypothesize that DC drive innate immune responses through early release of tumor necrosis factor (TNF) α, which drives airway epithelial cell responses. In a mouse model, TNFα release was significantly increased following a single exposure to German cockroach (GC) frass, an event independent of neutrophil recruitment into the airways. While lung epithelial cells and alveolar macrophages failed to release TNFα following GC frass exposure, bone marrow-derived DC (BMDC) produced substantial amounts of TNFα suggesting their importance as early responding cells. This was confirmed by flow cytometry of pulmonary myeloid DC. Addition of GC frass-pulsed BMDC or conditioned media from GC frass-pulsed BMDC to primary mouse tracheal epithelial cells (MTEC) or MLE-15 cells induced chemokine (C-C) motif ligand (CCL) 20 and granulocyte macrophage (GM) colony-stimulating factor (CSF), both of which are important for DC recruitment, survival and differentiation. Importantly, DC do not produce CCL20 or GM-CSF following allergen exposure. Blocking TNFα receptor 1 (TNFR1) completely abolished chemokine production, suggesting that BMDC-derived TNFα induced airway epithelial cell activation and enhancement of the innate immune response. Lastly, blocking TNFR1 in vivo resulted in significantly decreased CCL20 and GM-CSF production in the lungs of mice. Together, our data strongly suggest that DC-derived TNFα plays a crucial role in the initiation of innate immune responses through the modification of airway epithelial cell responses.
© 2012 S. Karger AG, Basel
Asthma is a common chronic disorder of the airways which is the result of an aberrant response to ubiquitous, otherwise innocuous environmental proteins or allergens at the airway mucosa. While the main immune function of the mucosal epithelium was initially thought to be a physical barrier, it is now accepted that it also plays an important role in modulating innate immune responses. Many investigators have suggested that asthmatic individuals may have a dysfunctional airway epithelium which is characterized by abnormal cytokine responses and impaired barrier function. Evidence for defective epithelial repair was suggested in a number of studies. Epidermal growth factor (EGF) receptor expression was significantly increased in mild and severe asthmatic epithelium and was positively correlated with subepithelial reticular membrane thickening . Airway epithelial cells from individuals with asthma display abnormal EGF release, plasminogen activator inhibitor-1 expression and extracellular matrix production, including cytokeratin 19 and fibronectin, all of which have been associated with defective repair in asthma [2,3,4]. Nasal epithelial cells and primary bronchial epithelial cells from asthmatic individuals were shown to release significantly greater amounts of interleukin (IL)-8 and granulocyte macrophage (GM) colony-stimulating factor (CSF) than from non-asthmatic individuals [5,6]. However, while a subsequent study showed no significant difference in IL-8 and GM-CSF levels in normal and asthmatic bronchial epithelial cells from epithelial brushings, asthmatic epithelial cells showed an increased response to tumor necrosis factor (TNF) α regarding the production of transforming growth factor (TGF) α . Thus, the airway epithelium may be regulated by the conditions in the airway microenvironment, but there may also be fundamental changes in the airway epithelium in patients with asthma.
TNFα is a proinflammatory cytokine that has been implicated in many aspects of airway pathology in asthma. TNFα was shown to be required for airway hyperresponsiveness, eosinophilia, increased Th2 and Th17 cytokines and pulmonary inflammation using a murine model of ovalbumin-induced pulmonary allergic inflammation in the absence of adjuvant . Increased levels of TNFα have been found in asthmatic airways [9,10]; recently, repeated low-dose allergen exposure was shown to upregulate TNFα production in the airways of human subjects with mild asthma . Importantly, TNFα can directly affect airway epithelial cell production of a number of cytokines and chemokines, including chemokine C-C motif ligand 20 (CCL20) , a unique ligand for the chemokine CCR6 which is expressed on circulating immature dendritic cells (DC) , and GM-CSF , which is important for DC recruitment, survival and differentiation. This suggests that TNFα may be important in the initiation of the allergic airway response as well as in the maintenance of airway inflammation.
Recently, we showed a significant release of TNFα within 3 h following a single exposure to the allergen German cockroach (GC) frass that was maintained at 6 h and returned to baseline levels 24 h after challenge . While we did not identify the source of TNFα, based on the kinetics following a single exposure to allergen in naïve mice, it is possible that this early release of TNFα could play a role in the activation of airway epithelial cells, possibly to direct or augment their response to allergen exposure. The main cellular source of TNFα in allergic airway inflammation is thought to be from preformed stores in mast cells and released during IgE-mediated reactions ; however mast cells would not be present at the initial encounter with allergen. Recently, myeloid DC (mDC) were shown to produce TNFα following allergen challenge  and these cells could be a likely source of the early increase in TNFα. Mucosal DC are intimately associated with the mucosal epithelium and extend dendrites through the tight junctions between epithelial cells to survey the airways . Jahnsen et al.  confirmed the presence of intraepithelial DC populations and found these constituted approximately 20% of the total airway mucosal DC. Thus DC are not only important as antigen-presenting cells which bridge innate and adaptive immune responses but, due to their location, may also serve as a trigger in innate immune responses. Therefore, based on the finding that mDC were shown to produce TNFα following allergen challenge , we hypothesized that the mucosal DC is a prime initiator of very early innate immune responses by secreting significant amounts of TNFα, which in turn acts directly on airway epithelium to induce cytokine and chemokine production. The end effect is the ability of the DC to alter the airway microenvironment leading to the modification of epithelial cell responses.
The fecal remnants (frass) from one cage of GC were transferred to a sterile container and stored at 4°C. GC frass was resuspended in PBS (divalent free; Gibco/Invitrogen, Carlsbad, Calif., USA) made with endotoxin-free double-distilled water (2 h at 4°C while rocking). Extracts were centrifuged to remove debris (10,000 g for 5 min at 4°C), supernatants were harvested, and total protein was measured using the Bio-Rad Protein Assay Dye (Bio-Rad, Hercules, Calif., USA).
Six-week-old female BALB/c mice were obtained from the Jackson Laboratory (Bar Harbor, Me., USA). Mice were anesthetized with ketamine (45 mg/kg)/xylazine (8 mg/kg) prior to PBS or GC frass (40 µg/40 µl) exposure by a single inhalation as described previously [20,21,22]. Mice were given a lethal dose of sodium pentobarbital 1–3 h later. In one experiment, mice were injected intraperitoneally with the anti-granulocyte monoclonal antibody (mAb) Rb5-8C5 (also referred to as Ly6g; BD Pharmingen, San Diego, Calif., USA) at a concentration of 100 µg/mouse  24 h before inhalation. In another experiment, hamster IgG isotype control antibody or mouse TNF receptor (TNFR) 1 antibody (R&D Systems, Minneapolis, Minn., USA) was instilled once into the airways (25 µg/mouse). Twenty-four hours later, mice were given a single treatment with PBS or GC frass and sacrificed 3 h later. Animal care was provided in accordance with NIH guidelines. These studies were approved by the Cincinnati Children’s Hospital Medical Center Institutional Animal Care and Use Committee.
Lungs were lavaged with 1 ml of Hanks balanced salt solution without calcium or magnesium. The lavage fluid was centrifuged (300 g for 10 min), and the supernatant was removed and immediately stored at –80°C. Bronchoalveolar lavage (BAL) fluid was analyzed for TNFα, CCL20 and GM-CSF using ELISA kits purchased from R&D Systems.
Mice were given a lethal dose of sodium pentobarbital prior to tibias and femur removal. Bone marrow cells (1.5 × 107 cells/ml) were cultured on complete RPMI supplemented with GM-CSF (10 ng/ml; Peprotech, Rocky Hills, N.J., USA). Fresh media was added along with GM-CSF (10 ng/ml) on day 3. On day 6, cells were washed, counted and plated (1 × 106 cells/ml) for experimentation. Cells were then treated with endotoxin-free PBS or GC frass (1 µg/ml) for 18 h. Cytokine levels were assessed following clarification of the cell culture media (13,000 g for 5 min at 4°C). Bone marrow-derived DC (BMDC) were >95% mDC as characterized by CD11c+, CD11b+, Gr1– and PDCA– (data not shown).
BMDC (5 × 106) were treated with or without GC frass (1 µg/ml) for 4 h. RNA was extracted using a standard TRIzol method of phenol extraction. Total RNA was converted to cDNA by reverse transcription using the Superscript first-strand synthesis system kit (Invitrogen). The TNFα primers used were 5′-AGCCCCCAGTCTGTATCCTT-3′ and 5′-CTCCCTTTGCAGAACTCAGG-3′, and the β-actin primers used were 5′-TGTTACCAACTGGGACGACA-3′ and 5′-GGGGTGTTGAAGGTCTCAAA-3′. Amplification was performed by PCR using SYBR Green on the iCycler (Bio-Rad Laboratories) as follows: 1 cycle at 95°C for 3 min, followed by 40 cycles at 95°C for 5 s, 57°C for 5 s and 72°C for 10 s; 95°C for 1 min; 55°C for 1 min, and then a hold at 25°C. The target gene was normalized to the reference gene using the method of Pfaffl .
The lungs of naïve BALB/c mice were lavaged three times with sterile PBS. The lavage fluid was centrifuged (300 g for 10 min), and cells were counted and plated at 5 × 105 cells/well in 12-well plates. Cells were treated with or without GC frass (1 µg/ml) and supernatants were harvested 18 h later for analysis of TNFα by ELISA (R&D Systems, Minneapolis, Minn., USA).
Tracheas from 4-week-old mice were removed from the thyroid cartilage to the level of the bifurcation and incubated in Pronase (1 mg/ml; Roche Applied Science, Indianapolis, Ind., USA) and incubated (18 h at 4°C while rocking). The next day, 10% FBS and 1 mg/ml DNase (Sigma-Aldrich, St. Louis, Mo., USA) was added to the tube and inverted multiple times. The trachea was discarded; cells were washed and plated onto a cell culture plate with Primaria surface treatment (BD Biosciences, Bedford, Mass., USA) for 4 h to remove fibroblasts. Non-attached cells were washed, counted and plated in DMEM/F12 (50/50) containing L-glutamine (2 mM), penicillin (100 U/ml)/streptomycin (100 µg/ml), NaHCO3 (3.6 mM), FBS (5%), cholera toxin (0.1 µg/ml), mouse EGF (0.5 ng/ml), amphotericin B (0.25 µg/ml), bovine pituitary extract (50 µg/ml), insulin-transferrin-selenium medium supplement (Sigma, St. Louis, Mo., USA) and retinoic acid (0.1 ng/ml). Mouse tracheal endothelial cells (MTEC) were grown on collagen-coated culture plates until confluent. Cells were treated with PBS or GC frass (1 µg/ml) for 18 h. In some cases, MTEC medium was removed and replaced with cell-free conditioned media (CM) from PBS- or GC frass-treated BMDC for 18 h. Supernatants were harvested, clarified and analyzed for CCL20 and GM-CSF by ELISA.
MLE-15 cells [25 ](a gift from Dr. Jeffrey Whitsett, Cincinnati Children’s Hospital, Cincinnati, Ohio, USA) were cultured in HITES medium (RPMI 1640 medium; Invitrogen) supplemented with 10 nM hydrocortisone, 5 µg/ml insulin, 5 µg/ml human transferrin, 10 nM β-estradiol, 5 µg/ml selenium, 2 mML-glutamine, 10 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin and 2% FBS. Upon confluence, cells were treated with GC frass (1 µg/ml), TNFα (10 ng/ml) or both together for 18 h. In some cases, media were removed and cell-free CM from PBS- or GC frass-treated BMDC was added. In some experiments, a TNFR1-blocking antibody (1 µg/ml; R&D Systems) or a control antibody (1 µg/ml; Santa Cruz, Santa Cruz, Calif., USA) was added immediately following the addition of DC-CM onto the MLE-15 cells. To directly add BMDC to MLE-15 cells, BMDC were treated with PBS or GC frass (1 µg/ml) for 6 h, washed with PBS twice and counted, and 1 × 106 cells were co-cultured with MLE-15 cells and incubated for 18 h. In all experiments, 18 h later, the supernatant was harvested, clarified by centrifugation (10,000 g × 10 min × 4°C) and analyzed for CCL20 and GM-CSF by ELISA.
Following inhalation of PBS or GC frass (40 µg/40 µl), whole lungs were isolated from mice, minced and placed in RPMI 1640 containing Liberase CI (0.5 mg/ml; Roche Diagnostics, Indianapolis, Ind., USA) and DNase I (0.5 mg/ml; Sigma) at 37°C for 45 min. The tissue was forced through a 70-µm cell strainer, and red blood cells were lysed with ACK lysis buffer (Invitrogen). Cells were washed with RPMI containing 10% FBS, counted and plated at 350,000 cells/well in a 96-well plate. Cells were immediately fixed and permeabilized (BD Cytofix/Cytoperm Plus with BD GolgiPlug). Cells were blocked with Fc block (mAb 2.4G2) for 30 min at 4°C. Staining was performed in Fc block with the permeabilization buffers at 4°C following incubation. mDC (CD11c+, CD11b+, Gr1–, CD317–) were quantified using anti-CD11c-APC (HL3), anti-CD11b-PE-Cy7 (M1/70) and anti GR-1-APC-Cy7 (RB6-8C5). TNFα expression was examined using PE-conjugated mAb to TNFα. All antibodies and reagents were purchased from eBioscience (San Diego, Calif., USA). Data were acquired with an LSRII flow cytometer (BD Biosciences, San Jose, Calif., USA). Spectral overlap was compensated using the FACSDiVa software (BD Biosciences) and analyzed using FlowJo software (Treestar, Ashland, Oreg., USA).
Statistical significance was assessed by Student’s t test or by one-way analysis of variance (ANOVA), as appropriate (SigmaPlot version 11; Systat Software, Chicago, Ill., USA). Differences identified by ANOVA were pinpointed by Student-Newman-Keuls’ multiple range test.
Naïve BALB/c mice were exposed to a single intratracheal inhalation of PBS or GC frass and sacrificed 1 and 3 h later. TNFα levels were measured in the BAL fluid of these mice. Within 1 h of allergen exposure, TNFα significantly increased (fig. 1a). At this time point, there was a trend towards increased neutrophil infiltration into the lungs; however, these levels did not reach statistical significance (fig. 1b). By 3 h after allergen inhalation, TNFα levels were >30-fold higher than in mice that inhaled PBS (fig. 1c). There was also a significant increase in the number of newly recruited neutrophils in the lungs at this time point (fig. 1d). These data highlight the immediate response to GC frass which is mounted in vivo following exposure to a common allergen.
We wanted to determine if the immediate cytokine release was dependent on newly recruited neutrophils in the airways. Therefore, mice were pretreated with R6B-8C5 (an antibody that depletes circulating neutrophils ) 24 h before a single allergen exposure. BAL fluid was isolated 3 h after challenge and analyzed for TNFα expression and neutrophil recruitment. While pretreatment with R6B-8C5 antibody had no effect on TNFα levels in the BAL fluid of mice (fig. 2a), it totally abolished neutrophil recruitment into the BAL fluid (fig. 2b). These data indicate that the significant release of inflammatory cytokines at this very early time point following allergen exposure is not due to the release of neutrophils in the airways.
To determine the source of allergen-derived TNFα, we isolated MTEC and cultured them in the presence of GC frass (1 µg/ml) for 18 h. MTEC failed to release TNFα following stimulation with GC frass (table 1). We also tested the release of TNFα from MLE-15 cells, an immortalized cell line derived from alveolar type II epithelial cells, and found no increase in TNFα release following GC frass treatment (table 1). Next we isolated alveolar macrophages from naïve mice and treated them for 18 h ex vivo with GC frass (1 µg/ml). While TNFα production was induced, the levels were significantly lower than what we detected in the BAL fluid following allergen challenge (table 1). Since DC are intimately associated with airway epithelium and are continuously monitoring the airway environment, we queried the role of DC in TNFα production. We generated BMDC by culturing bone marrow cells in the presence of GM-CSF for 6 days which results in 95% of the cells becoming mDC, as characterized by flow cytometry (CD11c+, CD11b+, Gr1–, CD317–; data not shown). When treated with GC frass for 18 h, mDC released a significant amount of TNFα (table 1). TNFα released from DC occurred in a time-dependent manner, with a significant increase in TNFα within 1 h of exposure to GC frass (fig. 3a). GC frass induced TNFα mRNA levels 4 h following stimulation with GC frass (fig. 3b). Thus, our data confirm a role for DC in mediating TNFα release following exposure to an allergen and suggest the potential importance of these cells in the initiation of an early innate immune response.
To confirm that a single exposure to allergen could induce intracellular TNFα expression in pulmonary mDC, we performed a single intratracheal inhalation of GC frass and isolated the lungs 3 h later. The lungs were dissociated, immediately fixed and permeabilized, and then stained for flow cytometry. mDC (CD11c+, CD11b+, Gr1–) were analyzed for intracellular TNFα levels. Following GC frass exposure, the number of TNFα-positive mDC in the lung increased, while the numbers of TNFα-positive alveolar macrophages and neutrophils did not increase (table 2). Pulmonary mDC expressed a higher level of intracellular TNFα staining (fig. 4a), which corresponded to an increased percentage of TNFα-positive mDC (fig. 4b). The mean fluorescence intensity was not different between allergen-stimulated mDC and control mDC (fig. 4c) suggesting an overall higher number of mDC synthesizing TNFα. A similar profile was found when cells were incubated in the presence of monensin and brefeldin A overnight prior to fixation, permeabilization and staining for flow cytometry (data not shown). These data confirm that pulmonary mDC are capable of increased TNFα production following allergen exposure.
Next, we wanted to confirm the importance of TNFα in regulating respiratory epithelial cell production of CCL20 and GM-CSF. TNFα treatment significantly increased CCL20 and GM-CSF production in MLE-15 cells (fig. 5). Interestingly, GC frass was unable to significantly increase CCL20 or GM-CSF production. When TNFα and GC frass were added simultaneously, there was a synergistic increase in both CCL20 and GM-CSF production. These data confirm that epithelial cells respond to TNFα and suggest the possibility that TNFα reprograms epithelial cell responses to make them more susceptible to allergen exposure.
To confirm the role of DC-derived TNFα on modifying airway epithelial cell cytokine and chemokine production, we aimed to determine if CM from GC frass-treated BMDC was sufficient to regulate CCL20 production from epithelial cells. Consequently, we cultured BMDC and treated them with GC frass for 6 h. CM was removed, clarified and added to cultured primary MTEC; 18 h after the addition of BMDC-CM to MTEC; the supernatant was removed and analyzed for CCL20 production. It is important to note that BMDC do not secrete CCL20 or GM-CSF following exposure to GC frass (data not shown). We found that CM from GC frass-treated BMDC significantly increased CCL20 production from MTEC (fig. 6a) and MLE-15 cells (fig. 6b). To confirm that TNFα release from BMDC was responsible for the increase in CCL20 production from respiratory epithelial cells, we treated selected MLE-15 cells with a TNFR-neutralizing antibody. Blocking TNFR1 totally abolished CCL20 production (fig. 6c), suggesting a role for BMDC TNFα in activating MLE-15 cells to synthesize CCL20. Lastly, we wanted to confirm that residual GC frass that may be in the BMDC-CM is not responsible for the increase in CCL20 production. Therefore, BMDC were treated with GC frass for 6 h, cells were washed to remove any residual GC frass and BMDC were co-cultured with MLE-15 cells. Importantly, we found that GC frass-stimulated BMDC were sufficient to regulate MLE-15-induced production of CCL20 (fig. 6d). We confirmed that GC frass-conditioned BMDC media also increased GM-CSF production in primary MTEC (fig. 7a) and that blocking TNFR1 abolished GM-CSF production in MLE-15 cells (fig. 7b). Together these data suggest the likelihood that the DC can immediately respond to allergen exposure by releasing significant quantities of TNFα which then act on the airway epithelial cells via TNFR1 to mediate their production of CCL20 and GM-CSF in vitro.
To address the importance of TNFα release on the upregulation of CCL20 and GM-CSF in vivo, we administered a TNFR1 antibody intratracheally 24 h prior to the instillation of PBS or GC frass. Three hours after allergen challenge; BAL fluid was isolated and analyzed for CCL20, GM-CSF and TNFα. We found a significant decrease in CCL20 and GM-CSF production in the lung following inhibition of TNFR1 compared with an isotype control antibody (fig. 8). TNFα levels were largely unaffected (data not shown). These data highlight the importance of early TNFα release on cytokine production via TNFR1 in vivo.
In this report, we describe a paradigm in which DC play a crucial role in the initiation of innate immune responses via early release of TNFα, which modifies cytokine expression of airway epithelial cells and the ability of these cells to respond to allergen. A number of findings suggest that DC-derived TNFα is the crucial component in reprogramming the early responses of lung epithelial cells including (1) the early and substantial release of TNFα by BMDC and pulmonary DC but not airway or bronchoalveolar epithelial cells, neutrophils or alveolar macrophages; (2) CM from GC frass-pulsed DC modulate chemokine production from lung epithelial cells, and (3) blocking TNFR1 resulted in decreased CCL20 and GM-CSF production from lung epithelial cells in vitro and in vivo. The fact that TNFα is a potent stimulator of airway epithelial cells and many of the cytokines and chemokines produced by these epithelial cells are activated by TNFα lends credibility to the idea that TNFα initiates the innate immune response to allergen exposure. Our findings indicate that the early source of allergen-derived TNFα is from the early activation of airway mDC.
The importance of airway DC in the early response to allergen exposure is validated by the finding that airway mDC, but not alveolar macrophages or neutrophils, increased intracellular TNFα production 3 h after allergen challenge. By flow cytometry, we failed to detect significant increases in intracellular TNFα in alveolar macrophages and neutrophils, results correlating with our in vitro and in vivo studies and suggesting that mDC are the primary source of early TNFα release. Since only a small proportion of whole lung mDC are likely to encounter allergen, it is anticipated that only a proportion of all CD11c+CD11b+Gr1– cells in the whole lung will be TNFα+. However, we predict that the TNFα-producing DC are localized in the intraepithelial layer and that their production of TNFα is likely to be sufficient to regulate airway epithelial cell responses in the lung. Future studies will define the actual location of TNFα-producing mDC in the lung.
We have previously shown that GC extract alone was insufficient to induce IL-8 cytokine production using the human bronchial epithelial cell line 16HBE14o– and primary normal human bronchial epithelial cells, but synergistically increased TNFα-induced IL-8 expression [26,27,28]. These data would support a crucial role for the presence of TNFα in the airways when allergen is encountered. Other groups have shown that addition of GC extract alone was sufficient to induce IL-8 production in A549 (adenocarcinomic human alveolar epithelial cells) and H292 (human epithelial carcinoma) cell lines [29,30]. The differences between these studies and ours include the use of the carcinoma cells, which may have different responses to stimuli than normal cells, and the very high doses of cockroach extract (10–100 µg/ml) applied. The current study supports our earlier work in the fact that GC frass induced minimal CCL20 and GM-CSF production from MLE-15 cells; however, the combined treatment of TNFα and GC frass led to optimal chemokine production. Together these data suggest that the initial release of DC-derived TNFα alters the airway microenvironment to more marked response of airway and bronchoalveolar epithelial cells to allergen exposure.
Recently, TNFα was shown to enhance TGF-β1-driven epithelial-to-mesenchymal transition , suggesting that it could be a central component leading to the reprogramming of airway epithelial cell responses. In another study, DC cultured in the presence of lipopolysaccharides were able to secrete exovesicles containing TNFα into cell culture media. The TNFα-containing exovesicles were then internalized by epithelial cells through receptor-mediated endocytosis and resulted in IL-8, MCP-1 and G-CSF release from epithelial cells . This study was of particular interest as they also concluded that DC are important carriers of TNFα and are involved in the activation of airway epithelial cells. While we did not investigate the mechanism by which TNFα was secreted, we did note increased transcription of TNFα, suggesting upregulation of a signaling pathway leading to TNFα production. While beyond the scope of this study, it is likely that activation of pattern recognition receptors may play a role. Future studies will explore the mechanisms of pattern recognition receptor binding, including the role of endotoxin, lipoproteins and proteases, in activating mucosal DC to secrete TNFα. Since GC frass is complex and contains agonists for Toll-like receptors (TLR2 and TLR4) as well as serine proteases that activate PAR-2 [15,21,22], we anticipate the activation of mDC to be complex as well.
It is interesting to consider a role for the intraepithelial DC in modulating immune responses. The nature of DC is to become adapted to the highly specialized environment in which they are located . Based on the findings by Jahnsen et al.  who eloquently showed that airway mucosal DC represent a ‘maturational continuum’ as they progress through the subepithelial layers, it is possible that the CCL20 and GM-CSF released by airway epithelial cells following antigen exposure may aid in the maturation process of the underlying DC. In addition, it is known that TNFα aids in the maturation process of DC by increasing co-stimulatory molecule expression, cytokine production and T-cell activation . In addition, a recent study showed that DC-derived TNFα differed between mouse strains and that TNFα levels played a role in IL-17A production in the lung . We have recently shown an increase in IL-17A following a single exposure to GC frass, as well as following adoptive transfer of GC frass-pulsed mDC . While we did not address this in the current study, based on the work by Fei et al.  it is possible that the DC-derived TNFα could be mediating the increase in IL-17A. Together, these data could suggest that the early activation of DC to produce TNFα could both modify airway epithelial cell responses to allergen exposure as well as induce DC maturation for optimal allergen uptake and processing.
We acknowledge the artificial nature of culturing the mDC, alveolar macrophages and the primary tracheal epithelial cells and studying the kinetics following various treatments; however, we anticipate that the interactions between these cells play an important role in the magnitude of responses to inhaled antigen. While future studies will need to be performed in a more tightly controlled system, we believe our findings strongly suggest that mDC could be the initiators of very early innate immune responses and that this early release of TNFα by DC could begin the process towards the generation of allergic airway responses. Therapeutically, the options of targeting the DC may be less challenging than targeting the airway epithelium, and a more comprehensive investigation into the activation of DC may provide potential new therapeutic options for the treatment of allergic airway disorders in the future.
Dr. Kristen Page
Division of Critical Care Medicine, Cincinnati Children’s Hospital Medical Center
3333 Burnet Avenue, ML 7006
Cincinnati, OH 45229 (USA)
Tel. +1 513 636 3079, E-Mail email@example.com
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.